Related Experiment Videos
Clinical experience with low molecular weight heparins
Thrombosis Research. Supplement
|January 1, 1990
Summary
Low molecular weight heparins (LMWHs) offer effective antithrombotic therapy, often superior to standard heparin (SH) with once-daily dosing. Clinical trials show LMWHs are beneficial for preventing deep-vein thrombosis and pulmonary embolism.
Area of Science:
- Pharmacology
- Thrombosis Research
- Drug Development
Background:
- Standard heparin (SH) has limitations in efficacy and dosing frequency.
- Low molecular weight heparins (LMWHs) were developed to improve antithrombotic therapy.
- Structural heterogeneity of LMWHs may influence clinical outcomes.
Purpose of the Study:
- To evaluate the efficacy and safety of LMWHs compared to SH.
- To review clinical trial data on LMWH use in various patient populations.
- To assess the role of LMWHs in preventing thromboembolic events.
Main Methods:
- Systematic review of clinical trials.
- Comparative analysis of LMWH and SH efficacy and safety profiles.
- Analysis of LMWH use in orthopedic surgery, abdominal surgery, hemodialysis, and stroke patients.
Main Results:
- LMWHs demonstrate comparable or superior efficacy to SH with less frequent administration (once daily vs. twice or thrice daily).
- LMWHs are effective in preventing deep-vein thrombosis and pulmonary embolism across various clinical settings.
- Some LMWHs show enhanced effectiveness, particularly in orthopedic surgery.
Conclusions:
- LMWHs represent an effective and often more convenient alternative to SH for antithrombotic prophylaxis.
- Further research is needed to establish the role of LMWHs in treating deep-vein thrombosis and their bleeding profile compared to SH.